Analytical Immunopharmacology

项目摘要--核心A 分析免疫药理学核心(核心A)旨在满足特定的药物和生物 针对每一个U19研究项目的治疗发展需求，同时汲取其优势 现有的希望之城综合癌症中心(COHCCC)核心没有不必要的重复 服务的价值。核心A将与COHCCC核心以及U19密切协作 行政核心和分子图谱和生物信息学核心(核心B)提供特殊支持 所有拟议的研究项目和U19之间的合作。核心A的首要目标是 协助胶质母细胞瘤治疗网络(GTN)U19项目负责人进行药代动力学(PK)和 进行药效学(PD)相关研究，以支持拟议的临床试验。这项工作将是 通过利用Core在脑内微透析(ICMD)、分析 化学和分析免疫化学，以及使用最先进的仪器。整体而言 目标将通过以下具体目标来实现： 目的1.为U19研究人员提供相关神经PK分析的概念和分析支持 (例如，分析中枢神经系统中的药物和代谢物)。由核心A向U19调查人员提供的支持 这一目标将包括ICMD神经PK研究的所有方面，包括实验设计、分析方法 数据的开发、样本分析和最终解释。核心A由训练有素的人员组成 配备了分析仪器，这将是小分子定量分析的理想选择 (例如，LC-MS/MS和ICP-MS/MS)。 目的2.为U19研究人员提供相关神经性帕金森病的概念和分析支持 分析(例如，对中枢神经系统药物反应的生物标志物的分析)。核心A向U19提供支持 这一目标下的调查人员将包括ICMD神经PD研究的所有方面，包括实验设计， 分析方法的发展、样本分析和数据的最终解释。核心A将提供 年ICMD神经-PD研究背景下的免疫分析平台谱(例如Luminex和ELISA) 支持拟议的临床试验。

PROJECT SUMMARY – CORE A The Analytical Immunopharmacology Core (Core A) is designed to meet the specific drug and biologic therapeutic development needs of each of the U19 Research Projects and at the same time draw on the strength of the existing City of Hope Comprehensive Cancer Center (COHCCC) cores without unnecessary duplication of services. Core A will work closely and synergistically with COHCCC cores, as well as with the U19 Administrative Core and the Molecular Profiling and Bioinformatics Core (Core B) to provide exceptional support for all of the proposed Research Projects and inter-U19 collaborations. The overarching goals of Core A are to assist the Glioblastoma Therapeutics Network (GTN) U19 Project Leaders with pharmacokinetic (PK) and pharmacodynamic (PD) correlative studies performed in support of the proposed clinical trials. The work will be accomplished by leveraging the Core’s significant expertise in intracerebral microdialysis (ICMD), analytical chemistry, and analytical immunochemistry, as well as its access to state-of-the-art instrumentation. The overall purpose will be achieved through the following Specific Aims: Aim 1. Provide conceptual and analytical support to U19 investigators for correlative neuro-PK analyses (e.g., analysis of drugs and metabolites in the CNS). Support provided by Core A to U19 investigators under this aim will include all aspects of ICMD neuro-PK studies, including experimental design, analytical method development, sample analysis, and final interpretation of the data. Core A is staffed by highly trained personnel and equipped with analytical instrumentation that will be ideal for the quantitative analyses of small molecules (e.g., LC-MS/MS and ICP-MS/MS). Aim 2. Provide conceptual and analytical support to U19 investigators for their correlative neuro-PD analyses (e.g., analysis of biomarkers of drug response in the CNS). Support provided by Core A to U19 investigators under this aim will include all aspects of ICMD neuro-PD studies, including experimental design, analytical method development, sample analysis, and final interpretation of the data. Core A will provide a spectrum of immunoassay platforms (e.g., Luminex and ELISA) in the context of ICMD neuro-PD studies in support of the proposed clinical trials.